Performance of Screening Strategies for Latent Tuberculosis Infection in Patients with Inflammatory Bowel Disease: Results from the ENEIDA Registry of GETECCU

(1) Aims: Patients receiving antitumor necrosis factor (anti-TNF) therapy are at risk of developing tuberculosis (TB), usually due to the reactivation of a latent TB infection (LTBI). LTBI screening and treatment decreases the risk of TB. This study evaluated the diagnostic performance of different...

Full description

Bibliographic Details
Authors: Riestra, S; Taxonera, C; Zabana, Y; Carpio, D; Chaparro, M; Barrio, J; Rivero, M; Lopez-Sanroman, A; Esteve, M; de Francisco, R; Bastida, G; Garcia-Lopez, S; Manosa, M; Martin-Arranz, MD; Perez-Calle, JL; Guardiola, J; Munoz, F; Arranz, L; Cabriada, JL; Garcia-Sepulcre, MF; Navarro, M; Montoro-Huguet, MA; Ricart, E; Bermejo, F; Calvet, X; Piqueras, M; Garcia-Planella, E; Marquez, L; Minguez, M; Van Domselar, M; Bujanda, L; Aldeguer, X; Sicilia, B; Iglesias, E; Alcain, G; Perez-Martinez, I; Rolle, V; Castano-Garcia, A; Gisbert, JP; Domenech, E
Format: Article
Status:Published version
Publication date:2022
Country:España
Institution:Institut d'Investigació i Innovació Parc Taulí (I3PT)
Repository:r-I3PT. Repositorio Institucional Producción Científica del Institut d'Investigació i Innovació Parc Taulí
OAI Identifier:oai:i3pt.fundanetsuite.com:p1288
Online Access:https://i3pt.portalinvestigacion.com/publicaciones/1288
https://www.scopus.com/inward/record.uri?eid=2-s2.0-85137377290&doi=10.3390%2fjcm11133915&partnerID=40&md5=12d7caba530e15adc4d684910ca33a56
Access Level:Open access
Keyword:inflammatory bowel disease
latent tuberculosis infection
tuberculin skin test
interferon gamma release assays
_version_ 1878731352000430080
author Riestra, S
author2 Taxonera, C
Zabana, Y
Carpio, D
Chaparro, M
Barrio, J
Rivero, M
Lopez-Sanroman, A
Esteve, M
de Francisco, R
Bastida, G
Garcia-Lopez, S
Manosa, M
Martin-Arranz, MD
Perez-Calle, JL
Guardiola, J
Munoz, F
Arranz, L
Cabriada, JL
Garcia-Sepulcre, MF
Navarro, M
Montoro-Huguet, MA
Ricart, E
Bermejo, F
Calvet, X
Piqueras, M
Garcia-Planella, E
Marquez, L
Minguez, M
Van Domselar, M
Bujanda, L
Aldeguer, X
Sicilia, B
Iglesias, E
Alcain, G
Perez-Martinez, I
Rolle, V
Castano-Garcia, A
Gisbert, JP
Domenech, E
author2_role author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author_browse Alcain, G
Aldeguer, X
Arranz, L
Barrio, J
Bastida, G
Bermejo, F
Bujanda, L
Cabriada, JL
Calvet, X
Carpio, D
Castano-Garcia, A
Chaparro, M
Domenech, E
Esteve, M
Garcia-Lopez, S
Garcia-Planella, E
Garcia-Sepulcre, MF
Gisbert, JP
Guardiola, J
Iglesias, E
Lopez-Sanroman, A
Manosa, M
Marquez, L
Martin-Arranz, MD
Minguez, M
Montoro-Huguet, MA
Munoz, F
Navarro, M
Perez-Calle, JL
Perez-Martinez, I
Piqueras, M
Ricart, E
Riestra, S
Rivero, M
Rolle, V
Sicilia, B
Taxonera, C
Van Domselar, M
Zabana, Y
de Francisco, R
author_facet Riestra, S
Taxonera, C
Zabana, Y
Carpio, D
Chaparro, M
Barrio, J
Rivero, M
Lopez-Sanroman, A
Esteve, M
de Francisco, R
Bastida, G
Garcia-Lopez, S
Manosa, M
Martin-Arranz, MD
Perez-Calle, JL
Guardiola, J
Munoz, F
Arranz, L
Cabriada, JL
Garcia-Sepulcre, MF
Navarro, M
Montoro-Huguet, MA
Ricart, E
Bermejo, F
Calvet, X
Piqueras, M
Garcia-Planella, E
Marquez, L
Minguez, M
Van Domselar, M
Bujanda, L
Aldeguer, X
Sicilia, B
Iglesias, E
Alcain, G
Perez-Martinez, I
Rolle, V
Castano-Garcia, A
Gisbert, JP
Domenech, E
author_role author
collection r-I3PT. Repositorio Institucional Producción Científica del Institut d'Investigació i Innovació Parc Taulí
description (1) Aims: Patients receiving antitumor necrosis factor (anti-TNF) therapy are at risk of developing tuberculosis (TB), usually due to the reactivation of a latent TB infection (LTBI). LTBI screening and treatment decreases the risk of TB. This study evaluated the diagnostic performance of different LTBI screening strategies in patients with inflammatory bowel disease (IBD). (2) Methods: Patients in the Spanish ENEIDA registry with IBD screened for LTBI between January 2003 and January 2018 were included. The diagnostic yield of different strategies (dual screening with tuberculin skin test [TST] and interferon-gamma-release assay [IGRA], two-step TST, and early screening performed at least 12 months before starting biological treatment) was analyzed. (3) Results: Out of 7594 screened patients, 1445 (19%; 95% CI 18-20%) had LTBI. Immunomodulator (IMM) treatment at screening decreased the probability of detecting LTBI (20% vs. 17%, p = 0.001). Regarding screening strategies, LTBI was more frequently diagnosed by dual screening than by a single screening strategy (IGRA, OR 0.60; 95% CI 0.50-0.73, p < 0.001; TST, OR 0.76; 95% CI 0.66-0.88, p < 0.001). Two-step TST increased the diagnostic yield of a single TST by 24%. More cases of LTBI were diagnosed by early screening than by routine screening before starting anti-TNF agents (21% [95% CI 20-22%] vs. 14% [95% CI 13-16%], p < 0.001). The highest diagnostic performance for LTBI (29%) was obtained by combining early and TST/IGRA dual screening strategies in patients without IMM. (4): Conclusions: Both early screening and TST/IGRA dual screening strategies significantly increased diagnostic performance for LTBI in patients with IBD, with optimal performance achieved when they are used together in the absence of IMM.
eu_rights_str_mv openAccess
format article
id ES_2dd67c040c7daf6bcc058d8a0d5236e6
institution Institut d'Investigació i Innovació Parc Taulí (I3PT)
instname_str Institut d'Investigació i Innovació Parc Taulí (I3PT)
network_acronym_str ES
network_name_str España
oai_identifier_str oai:i3pt.fundanetsuite.com:p1288
publishDate 2022
publishDateSort 2022
publisher MDPI
publisherStr MDPI
reponame_str r-I3PT. Repositorio Institucional Producción Científica del Institut d'Investigació i Innovació Parc Taulí
spelling Performance of Screening Strategies for Latent Tuberculosis Infection in Patients with Inflammatory Bowel Disease: Results from the ENEIDA Registry of GETECCU Riestra, S Taxonera, C Zabana, Y Carpio, D Chaparro, M Barrio, J Rivero, M Lopez-Sanroman, A Esteve, M de Francisco, R Bastida, G Garcia-Lopez, S Manosa, M Martin-Arranz, MD Perez-Calle, JL Guardiola, J Munoz, F Arranz, L Cabriada, JL Garcia-Sepulcre, MF Navarro, M Montoro-Huguet, MA Ricart, E Bermejo, F Calvet, X Piqueras, M Garcia-Planella, E Marquez, L Minguez, M Van Domselar, M Bujanda, L Aldeguer, X Sicilia, B Iglesias, E Alcain, G Perez-Martinez, I Rolle, V Castano-Garcia, A Gisbert, JP Domenech, E inflammatory bowel disease latent tuberculosis infection tuberculin skin test interferon gamma release assays (1) Aims: Patients receiving antitumor necrosis factor (anti-TNF) therapy are at risk of developing tuberculosis (TB), usually due to the reactivation of a latent TB infection (LTBI). LTBI screening and treatment decreases the risk of TB. This study evaluated the diagnostic performance of different LTBI screening strategies in patients with inflammatory bowel disease (IBD). (2) Methods: Patients in the Spanish ENEIDA registry with IBD screened for LTBI between January 2003 and January 2018 were included. The diagnostic yield of different strategies (dual screening with tuberculin skin test [TST] and interferon-gamma-release assay [IGRA], two-step TST, and early screening performed at least 12 months before starting biological treatment) was analyzed. (3) Results: Out of 7594 screened patients, 1445 (19%; 95% CI 18-20%) had LTBI. Immunomodulator (IMM) treatment at screening decreased the probability of detecting LTBI (20% vs. 17%, p = 0.001). Regarding screening strategies, LTBI was more frequently diagnosed by dual screening than by a single screening strategy (IGRA, OR 0.60; 95% CI 0.50-0.73, p < 0.001; TST, OR 0.76; 95% CI 0.66-0.88, p < 0.001). Two-step TST increased the diagnostic yield of a single TST by 24%. More cases of LTBI were diagnosed by early screening than by routine screening before starting anti-TNF agents (21% [95% CI 20-22%] vs. 14% [95% CI 13-16%], p < 0.001). The highest diagnostic performance for LTBI (29%) was obtained by combining early and TST/IGRA dual screening strategies in patients without IMM. (4): Conclusions: Both early screening and TST/IGRA dual screening strategies significantly increased diagnostic performance for LTBI in patients with IBD, with optimal performance achieved when they are used together in the absence of IMM. MDPI https://i3pt.portalinvestigacion.com/publicaciones/1288 https://www.scopus.com/inward/record.uri?eid=2-s2.0-85137377290&doi=10.3390%2fjcm11133915&partnerID=40&md5=12d7caba530e15adc4d684910ca33a56
spellingShingle Performance of Screening Strategies for Latent Tuberculosis Infection in Patients with Inflammatory Bowel Disease: Results from the ENEIDA Registry of GETECCU
Riestra, S
inflammatory bowel disease
latent tuberculosis infection
tuberculin skin test
interferon gamma release assays
status_str publishedVersion
title Performance of Screening Strategies for Latent Tuberculosis Infection in Patients with Inflammatory Bowel Disease: Results from the ENEIDA Registry of GETECCU
title_full Performance of Screening Strategies for Latent Tuberculosis Infection in Patients with Inflammatory Bowel Disease: Results from the ENEIDA Registry of GETECCU
title_fullStr Performance of Screening Strategies for Latent Tuberculosis Infection in Patients with Inflammatory Bowel Disease: Results from the ENEIDA Registry of GETECCU
title_full_unstemmed Performance of Screening Strategies for Latent Tuberculosis Infection in Patients with Inflammatory Bowel Disease: Results from the ENEIDA Registry of GETECCU
title_short Performance of Screening Strategies for Latent Tuberculosis Infection in Patients with Inflammatory Bowel Disease: Results from the ENEIDA Registry of GETECCU
title_sort Performance of Screening Strategies for Latent Tuberculosis Infection in Patients with Inflammatory Bowel Disease: Results from the ENEIDA Registry of GETECCU
topic inflammatory bowel disease
latent tuberculosis infection
tuberculin skin test
interferon gamma release assays
topic_facet inflammatory bowel disease
latent tuberculosis infection
tuberculin skin test
interferon gamma release assays
url https://i3pt.portalinvestigacion.com/publicaciones/1288
https://www.scopus.com/inward/record.uri?eid=2-s2.0-85137377290&doi=10.3390%2fjcm11133915&partnerID=40&md5=12d7caba530e15adc4d684910ca33a56